$OSCR

Schlosser Mario sold $749K of OSCR

Schlosser Mario sold 34,120 shares of Oscar Health, Inc. (OSCR) at an average of $21.94 ($21.74–$22.45, $0.75M total) across 2 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schlosser Mario
Published Jun 4, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The disclosed sale adds a modest negative signal for Oscar Health, but size is limited.

02

Market read

A routine insider sale with modest value; likely limited short-term price impact.

03

What to watch

Potential upcoming earnings or strategic moves not disclosed may be the real driver.

Relevance 4/10Novelty 4/10Timing: post-market filing

Background

Form 4 filing reports insider transactions; directors often use 10b5-1 plans for scheduled sales.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

Director Mario Schlosser sold 34,120 shares for $749K via a 10b5-1 plan.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

Director-level insider selling $749K is modest but could be interpreted as a negative signal.

Market effects

Minimal impact on health insurance sector; similar insider sales may be watched.

Limited to US markets where OSCR trades.

Low global relevance.

Counterpoint

The sale could be routine under a pre-arranged plan, not reflecting sentiment.

Key entities

  • Oscar Health, Inc.

    US-listed health insurance provider (ticker OSCR).

  • Mario Schlosser

    Director of Oscar Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.